AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00338026
Drug: ECO-4601
RxNorm normalized name: Eco-Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
Trial: NCT00374777
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01224496
Drug: Chinese herbal concoction twice a day for 6 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
Trial: NCT01390246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Bupropion SR placebo tablet
Trial: NCT00871559
Drug: REGN421(SAR153192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01485952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily administration (immediate release capsule)
Trial: NCT02279641
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02510157
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo controlled intervention
Trial: NCT00930358
Drug: general anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic intravenous route
Trial: NCT02422030
Drug: Lipitor Tab. 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02367313
Drug: Vapendavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapendavir 264 mg twice daily
Trial: NCT02367313
Drug: Vapendavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapendavir 528 mg twice daily
Trial: NCT02367313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT00718718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
Trial: NCT00718718
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stable dose of methotrexate will be maintained through Week 24.
Trial: NCT01085175
Drug: LMI 1195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus intravenous injection of LMI 1195
Trial: NCT04231435
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01886794
Drug: Postmenopausal, topical vaginal estrogen cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
Trial: NCT01886794
Drug: Placebo Comparator: Postmenopausal, topical placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
Trial: NCT00927927
Drug: NNC0142-0002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
Trial: NCT00927927
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
Trial: NCT00927927
Drug: NNC0142-0002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
Trial: NCT03403634
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02877485
Drug: Ayr saline nasal mist
RxNorm normalized name: Ayr Saline Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
Trial: NCT00363987
Drug: Ketosteril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Ketosteril/5kgBW/d
Trial: NCT01181895
Drug: Placebo Inhalation Powder NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Trial: NCT01181895
Drug: Placebo Inhalation Powder Diskus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder inhaled orally twice daily for 12 weeks
Trial: NCT00821691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo caps
Trial: NCT02177344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01363323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02066298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05095480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo receiving group
Trial: NCT04242199
Drug: INCB099280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
Trial: NCT02609126
Drug: EP-104IAR
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, ultrasound-guided injection of EP-104IAR into the knee
Trial: NCT02609126
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, ultrasound-guided injection of vehicle placebo into the knee
Trial: NCT01679119
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750mg/m2 IV, given day 1
Trial: NCT01679119
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 100mg OD Oral given days 1-5
Trial: NCT02348489
Drug: SGI-110 (guadecitabine)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational medicinal product
Trial: NCT02348489
Drug: Treatment Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of one: cytarabine, decitabine, or azacitidine
Trial: NCT01922596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151801
Drug: estroprogestins
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03788889
Drug: Placebo A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT03788889
Drug: Placebo B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT04244474
Drug: A single one ml injection
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
Trial: NCT00439400
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00439400
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02698501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 doses in total, 4-week intervals), administered intravenously
Trial: NCT03348904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for epacadostat administered orally twice daily.
Trial: NCT03003676
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-treatment
Trial: NCT03732638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to match rimegepant tablet EOD
Trial: NCT00268749
Drug: glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg/day
Trial: NCT00786916
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Trial: NCT00058890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily
Trial: NCT02322606
Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322606
Drug: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322606
Drug: TAK-137 5mg tablet, TAK-137 placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00572572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
Trial: NCT00816634
Drug: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks
Trial: NCT00081588
Drug: TMC114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
Trial: NCT01881451
Drug: 18F-EF5 PET/CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo an investigations 18F-EF5 PET/CT scan.
Trial: NCT04327934
Drug: GnRH antagonist + MethylTESTOSTERone 5 MG
RxNorm normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
Trial: NCT04153409
Drug: LAT8881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 30 mg capsules of LAT8881
Trial: NCT04153409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules of placebo
Trial: NCT03713619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300mg every 2 or every 4 weeks
Trial: NCT01850160
Drug: GROUP A: Valsartan plus Chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
Trial: NCT01678976
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg
Trial: NCT01678976
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets containing 300 mg and 600 mg of Trileptal®
Trial: NCT01711242
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01850160
Drug: GROUP C: Chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
Trial: NCT01490060
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
Trial: NCT04289649
Drug: K-924 LD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables
Trial: NCT04289649
Drug: K-924 HD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Trial: NCT04289649
Drug: K-924 LD Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastain 2 mg
Trial: NCT04289649
Drug: K-924 HD Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastain 4 mg
Trial: NCT02838121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IV aclasta
Trial: NCT02268773
Drug: Asasantin®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02268773
Drug: Acetylsalicylic acid low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02268773
Drug: Acetylsalicylic acid high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00383435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI twice a day for 26 weeks
Trial: NCT01063010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously for 90 minutes (+ 15 minutes)
Trial: NCT04574999
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel for vaginal application
Trial: NCT00770848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02464969
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Trial: NCT02799082
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Trial: NCT02181231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
Trial: NCT01713595
Drug: Hypertonic Saline Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 5ml dose of 7% Saline aerosol
Trial: NCT01175226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT00835406
Drug: Fosamax® Tablets 70mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 70 mg, single dose fasting
Trial: NCT00499889
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 on days 1, 3, 6 and 11.
Trial: NCT01769794
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
Trial: NCT01769794
Drug: JET
RxNorm normalized name: Saljet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
Trial: NCT01769794
Drug: Placebo(for JET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
Trial: NCT00851175
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7 day treatment with rosuvastatin 1dd 20mg
Trial: NCT00851175
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
Trial: NCT01438190
Drug: Placebo, gonadotropins in step-up regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
Trial: NCT02369133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02261116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02752048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 group: Placebo group. Oral administration for 24 weeks, BID after meal
Trial: NCT02605590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03110159
Drug: Levulan® Kerastick®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
Trial: NCT03110159
Drug: BLU-U Blue Light Photodynamic Therapy
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
Trial: NCT06038682
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
Trial: NCT00132769
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
Trial: NCT01108744
Drug: hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline, dosed by ideal patient weight
Trial: NCT03128749
Drug: Treatment as Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
Trial: NCT01802411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02520245
Drug: REGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive REGN2810 by intravenous (IV) infusion
Trial: NCT01956305
Drug: DS-7309
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-7309 powder in bottle
Trial: NCT01956305
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match DS-7309 powder in bottle
Trial: NCT04222283
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
RxNorm normalized name: Biktarvy 50mg-200mg-25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
Trial: NCT00806221
Drug: emollient (Cetaphil cream)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetaphil cream applied daily from birth
Trial: NCT03856229
Drug: Conventional steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
Trial: NCT03856229
Drug: Shortened steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14).
Trial: NCT03265405
Drug: Low dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.